Gene silencing of STAT6 with siRNA ameliorates contact hypersensitivity and allergic rhinitis

K. Hosoya, T. Satoh, Y. Yamamoto, K. Saeki, K. Igawa, M. Okano, T. Moriya, O. Imamura, Y. Nemoto, H. Yokozeki

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: Silencing of genes using small interfering RNA (siRNA) is a recently developed strategy to regulate the synthesis of target molecules. Signal transducer and activator of transcription 6 (STAT6) is a nuclear transcription factor that mediates Th2-type immunity. Methods: To elucidate the therapeutic potential of using siRNA to inhibit STAT6 in allergic reactions, we determined the nucleotide sequences of siRNA specific for STAT6. Results: The selected sequences of STAT6 siRNA specifically inhibited the generation of STAT6 synthesis in dermal fibroblasts and eotaxin (CCL11) production in response to IL-4/TNF-αin vitro. Local administration of STAT6 siRNA in vivo alleviated contact hypersensitivity responses to chemical haptens. This was accompanied by reduced local production of IL-4, IL-13, eotaxin (CCL11), TARC (CCL17) and MDC (CCL22). Similarly, consecutive intranasal instillation of STAT6 siRNA markedly inhibited inflammatory cellular infiltration of mucosal tissues in allergic rhinitis responses in association with reduced IL-4 and IL-5 production from regional lymph node cells. Immediate responses, such as sneezing and nasal rubbing behaviors, were also improved by STAT6 siRNA. Conclusions: Local administration of STAT6 siRNA is thus a promising therapeutic strategy for both Th2-mediated cutaneous diseases and allergic rhinitis.

Original languageEnglish
Pages (from-to)124-131
Number of pages8
JournalAllergy: European Journal of Allergy and Clinical Immunology
Volume66
Issue number1
DOIs
Publication statusPublished - Jan 2011

Fingerprint

STAT6 Transcription Factor
Contact Dermatitis
Gene Silencing
Small Interfering RNA
Interleukin-4
Sneezing
Allergic Rhinitis
Interleukin-13
Haptens
Interleukin-5
Nose
Skin Diseases
Immunity
Hypersensitivity
Mucous Membrane
Transcription Factors
Fibroblasts
Lymph Nodes

Keywords

  • contact sensitivity
  • eotaxin
  • lipofectamine
  • nasal allergy
  • siRNA
  • STAT6

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Gene silencing of STAT6 with siRNA ameliorates contact hypersensitivity and allergic rhinitis. / Hosoya, K.; Satoh, T.; Yamamoto, Y.; Saeki, K.; Igawa, K.; Okano, M.; Moriya, T.; Imamura, O.; Nemoto, Y.; Yokozeki, H.

In: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 66, No. 1, 01.2011, p. 124-131.

Research output: Contribution to journalArticle

Hosoya, K, Satoh, T, Yamamoto, Y, Saeki, K, Igawa, K, Okano, M, Moriya, T, Imamura, O, Nemoto, Y & Yokozeki, H 2011, 'Gene silencing of STAT6 with siRNA ameliorates contact hypersensitivity and allergic rhinitis', Allergy: European Journal of Allergy and Clinical Immunology, vol. 66, no. 1, pp. 124-131. https://doi.org/10.1111/j.1398-9995.2010.02440.x
Hosoya, K. ; Satoh, T. ; Yamamoto, Y. ; Saeki, K. ; Igawa, K. ; Okano, M. ; Moriya, T. ; Imamura, O. ; Nemoto, Y. ; Yokozeki, H. / Gene silencing of STAT6 with siRNA ameliorates contact hypersensitivity and allergic rhinitis. In: Allergy: European Journal of Allergy and Clinical Immunology. 2011 ; Vol. 66, No. 1. pp. 124-131.
@article{fd61538762534fd38d8e74659fb0a206,
title = "Gene silencing of STAT6 with siRNA ameliorates contact hypersensitivity and allergic rhinitis",
abstract = "Background: Silencing of genes using small interfering RNA (siRNA) is a recently developed strategy to regulate the synthesis of target molecules. Signal transducer and activator of transcription 6 (STAT6) is a nuclear transcription factor that mediates Th2-type immunity. Methods: To elucidate the therapeutic potential of using siRNA to inhibit STAT6 in allergic reactions, we determined the nucleotide sequences of siRNA specific for STAT6. Results: The selected sequences of STAT6 siRNA specifically inhibited the generation of STAT6 synthesis in dermal fibroblasts and eotaxin (CCL11) production in response to IL-4/TNF-αin vitro. Local administration of STAT6 siRNA in vivo alleviated contact hypersensitivity responses to chemical haptens. This was accompanied by reduced local production of IL-4, IL-13, eotaxin (CCL11), TARC (CCL17) and MDC (CCL22). Similarly, consecutive intranasal instillation of STAT6 siRNA markedly inhibited inflammatory cellular infiltration of mucosal tissues in allergic rhinitis responses in association with reduced IL-4 and IL-5 production from regional lymph node cells. Immediate responses, such as sneezing and nasal rubbing behaviors, were also improved by STAT6 siRNA. Conclusions: Local administration of STAT6 siRNA is thus a promising therapeutic strategy for both Th2-mediated cutaneous diseases and allergic rhinitis.",
keywords = "contact sensitivity, eotaxin, lipofectamine, nasal allergy, siRNA, STAT6",
author = "K. Hosoya and T. Satoh and Y. Yamamoto and K. Saeki and K. Igawa and M. Okano and T. Moriya and O. Imamura and Y. Nemoto and H. Yokozeki",
year = "2011",
month = "1",
doi = "10.1111/j.1398-9995.2010.02440.x",
language = "English",
volume = "66",
pages = "124--131",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Gene silencing of STAT6 with siRNA ameliorates contact hypersensitivity and allergic rhinitis

AU - Hosoya, K.

AU - Satoh, T.

AU - Yamamoto, Y.

AU - Saeki, K.

AU - Igawa, K.

AU - Okano, M.

AU - Moriya, T.

AU - Imamura, O.

AU - Nemoto, Y.

AU - Yokozeki, H.

PY - 2011/1

Y1 - 2011/1

N2 - Background: Silencing of genes using small interfering RNA (siRNA) is a recently developed strategy to regulate the synthesis of target molecules. Signal transducer and activator of transcription 6 (STAT6) is a nuclear transcription factor that mediates Th2-type immunity. Methods: To elucidate the therapeutic potential of using siRNA to inhibit STAT6 in allergic reactions, we determined the nucleotide sequences of siRNA specific for STAT6. Results: The selected sequences of STAT6 siRNA specifically inhibited the generation of STAT6 synthesis in dermal fibroblasts and eotaxin (CCL11) production in response to IL-4/TNF-αin vitro. Local administration of STAT6 siRNA in vivo alleviated contact hypersensitivity responses to chemical haptens. This was accompanied by reduced local production of IL-4, IL-13, eotaxin (CCL11), TARC (CCL17) and MDC (CCL22). Similarly, consecutive intranasal instillation of STAT6 siRNA markedly inhibited inflammatory cellular infiltration of mucosal tissues in allergic rhinitis responses in association with reduced IL-4 and IL-5 production from regional lymph node cells. Immediate responses, such as sneezing and nasal rubbing behaviors, were also improved by STAT6 siRNA. Conclusions: Local administration of STAT6 siRNA is thus a promising therapeutic strategy for both Th2-mediated cutaneous diseases and allergic rhinitis.

AB - Background: Silencing of genes using small interfering RNA (siRNA) is a recently developed strategy to regulate the synthesis of target molecules. Signal transducer and activator of transcription 6 (STAT6) is a nuclear transcription factor that mediates Th2-type immunity. Methods: To elucidate the therapeutic potential of using siRNA to inhibit STAT6 in allergic reactions, we determined the nucleotide sequences of siRNA specific for STAT6. Results: The selected sequences of STAT6 siRNA specifically inhibited the generation of STAT6 synthesis in dermal fibroblasts and eotaxin (CCL11) production in response to IL-4/TNF-αin vitro. Local administration of STAT6 siRNA in vivo alleviated contact hypersensitivity responses to chemical haptens. This was accompanied by reduced local production of IL-4, IL-13, eotaxin (CCL11), TARC (CCL17) and MDC (CCL22). Similarly, consecutive intranasal instillation of STAT6 siRNA markedly inhibited inflammatory cellular infiltration of mucosal tissues in allergic rhinitis responses in association with reduced IL-4 and IL-5 production from regional lymph node cells. Immediate responses, such as sneezing and nasal rubbing behaviors, were also improved by STAT6 siRNA. Conclusions: Local administration of STAT6 siRNA is thus a promising therapeutic strategy for both Th2-mediated cutaneous diseases and allergic rhinitis.

KW - contact sensitivity

KW - eotaxin

KW - lipofectamine

KW - nasal allergy

KW - siRNA

KW - STAT6

UR - http://www.scopus.com/inward/record.url?scp=78649995661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649995661&partnerID=8YFLogxK

U2 - 10.1111/j.1398-9995.2010.02440.x

DO - 10.1111/j.1398-9995.2010.02440.x

M3 - Article

VL - 66

SP - 124

EP - 131

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

SN - 0105-4538

IS - 1

ER -